Tumor Microenvironment Versus Cancer Stem Cells in Cholangiocarcinoma: Synergistic Effects?

Cholangiocarcinoma (CCAs) may be defined as tumors that derived from the biliary tree with the differentiation in the biliary epithelial cells. This tumor is malignant, extremely aggressive with a poor prognosis. It can be treated surgically and its pathogenesis is poorly understood. The tumor microenvironment (TME) is a very important factor in the regulation of tumor angiogenesis, invasion, and metastasis. Besides cancer stem cells (CSCs) can modulate tumor growth, stroma formation, and migratory capability. The initial stage of tumorigenesis is characterized by genetic mutations and epigenetic alterations due to intrinsic factors which lead to the generation of oncogenes thus inducing tumorigenesis. CSCs may result from precancerous stem cells, cell de‐differentiation, normal stem cells, or an epithelial‐mesenchymal transition (EMT). CSCs have been found in the cancer niche, and EMT may occur early within the tumor microenvironment. Previous studies have demonstrated evidence of cholangiocarcinoma stem cells (CD133, CD24, EpCAM, CD44, and others) and the presence of these markers has been associated with malignant potential. The interaction between TME and cholangiocarcinoma stem cells via signaling mediators may create an environment that accommodates tumor growth, yielding resistance to cytotoxic insults (chemotherarapeutic). While progress has been made in the understanding of the mechanisms, the interactions in the tumorigenic process still remain a major challenge. Our review, addresses recent concepts of TME‐CSCs interaction and will emphasize the importance of early detection with the use of novel diagnostic mechanisms such as CCA–CSC biomarkers and the importance of tumor stroma to define new treatments. J. Cell. Physiol. 231: 768–776, 2016. © 2015 Wiley Periodicals, Inc.

[1]  S. Pignata,et al.  Identification of a distinct population of CD133+CXCR4+ cancer stem cells in ovarian cancer , 2015, Scientific Reports.

[2]  Qian He,et al.  TGF-β1 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma , 2015, Biological Research.

[3]  G. Pirozzi,et al.  Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma , 2015, Oncoscience.

[4]  A. Rashid,et al.  miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells. , 2015, Cancer research.

[5]  V. Orian-Rousseau CD44 Acts as a Signaling Platform Controlling Tumor Progression and Metastasis , 2015, Front. Immunol..

[6]  M. Sadeghizadeh,et al.  Transcription factor decoy against stem cells master regulators, Nanog and Oct-4: a possible approach for differentiation therapy , 2015, Tumor Biology.

[7]  S. Barry,et al.  WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. , 2015, The Journal of clinical investigation.

[8]  L. Lv,et al.  Chemotherapy targeting cancer stem cells. , 2015, American journal of cancer research.

[9]  R. Bristow,et al.  Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression , 2014, Oncotarget.

[10]  J. Xu,et al.  Transforming growth factor-β1-induced epithelial-mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma. , 2014, Cancer letters.

[11]  K. Boudjema,et al.  Epithelial cell adhesion molecule is a prognosis marker for intrahepatic cholangiocarcinoma. , 2014, The Journal of surgical research.

[12]  Kosei Maemura,et al.  Molecular mechanism of cholangiocarcinoma carcinogenesis , 2014, Journal of hepato-biliary-pancreatic sciences.

[13]  A. Mock,et al.  Microenvironment and brain tumor stem cell maintenance: impact of the niche. , 2014, Anti-cancer agents in medicinal chemistry.

[14]  H. Saya,et al.  Tumor necrosis factor‐α modulates epithelial mesenchymal transition mediators ZEB2 and S100A4 to promote cholangiocarcinoma progression , 2014, Journal of hepato-biliary-pancreatic sciences.

[15]  B. Calenic,et al.  Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics. , 2014, World journal of gastroenterology.

[16]  I. Chowdhury,et al.  Prohibitins Role in Cellular Survival Through Ras‐Raf‐MEK‐ERK Pathway , 2014, Journal of cellular physiology.

[17]  W. Cui,et al.  Sox2, a key factor in the regulation of pluripotency and neural differentiation. , 2014, World journal of stem cells.

[18]  Qiang Sun,et al.  Role of the Embryonic Protein SOX2 in Cholangiocarcinoma , 2014, Cell Biochemistry and Biophysics.

[19]  Lei-bo Xu,et al.  Clinicopathological significance of aberrant Notch receptors in intrahepatic cholangiocarcinoma. , 2014, International journal of clinical and experimental pathology.

[20]  M. De la Fuente,et al.  Chronic Inflammation and Cytokines in the Tumor Microenvironment , 2014, Journal of immunology research.

[21]  R. Khokha,et al.  High CD49f expression is associated with osteosarcoma tumor progression: a study using patient-derived primary cell cultures , 2014, Cancer medicine.

[22]  S. Kaneko,et al.  Molecular Biology of Liver Cancer Stem Cells , 2014, Liver Cancer.

[23]  M. Kim,et al.  Hedgehog Signaling Between Cancer Cells and Hepatic Stellate Cells in Promoting Cholangiocarcinoma , 2014, Annals of Surgical Oncology.

[24]  M. Rinaldo,et al.  The role of CD44+/CD24-/low biomarker for screening, diagnosis and monitoring of breast cancer. , 2014, Oncology reports.

[25]  E. Boscolo,et al.  α6‐Integrin Is Required for the Adhesion and Vasculogenic Potential of Hemangioma Stem Cells , 2014, Stem cells.

[26]  B. Jang,et al.  Clinicopathologic Significance of Sox2, CD44 and CD44v6 Expression in Intrahepatic Cholangiocarcinoma , 2014, Pathology & Oncology Research.

[27]  Kol Jia Yong,et al.  SALL4 is a new target in endometrial cancer , 2013, Oncogene.

[28]  C. Wongkham,et al.  Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangiocarcinoma patients with poor prognosis. , 2013, Free radical biology & medicine.

[29]  D. Kaigler,et al.  Bone marrow-derived mesenchymal stem cells enhance angiogenesis via their α6β1 integrin receptor. , 2013, Experimental cell research.

[30]  Wai Leong Tam,et al.  The epigenetics of epithelial-mesenchymal plasticity in cancer , 2013, Nature Medicine.

[31]  R. Tohtong,et al.  CD24 induces the invasion of cholangiocarcinoma cells by upregulating CXCR4 and increasing the phosphorylation of ERK1/2 , 2013, Oncology letters.

[32]  Qi Zhou,et al.  Inhibition of Wnt signaling induces cell apoptosis and suppresses cell proliferation in cholangiocarcinoma cells. , 2013, Oncology reports.

[33]  S. Chieffi,et al.  Molecular biomarkers as potential targets for therapeutic strategies in human testicular germ cell tumors: An overview , 2013, Journal of cellular physiology.

[34]  M. Niu,et al.  Downregulation of CD24 inhibits invasive growth, facilitates apoptosis and enhances chemosensitivity in gastric cancer AGS cells. , 2013, European review for medical and pharmacological sciences.

[35]  M. Manns,et al.  A Critical Role for Notch Signaling in the Formation of Cholangiocellular Carcinomas. , 2013, Cancer cell.

[36]  E. Raymond,et al.  Targeting the Ras–ERK pathway in pancreatic adenocarcinoma , 2013, Cancer and Metastasis Reviews.

[37]  R. Franco,et al.  Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer. , 2013, Oncology reports.

[38]  X. Wang,et al.  Sal‐like protein 4 (SALL4), a stem cell biomarker in liver cancers , 2013, Hepatology.

[39]  Jin‐Young Jang,et al.  CD24 expression predicts distant metastasis in extrahepatic bile duct cancer. , 2013, World journal of gastroenterology.

[40]  Premkumar Vummidi Giridhar,et al.  CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches , 2013, Experimental biology and medicine.

[41]  Giovanni Simone,et al.  Co‐expression of CD133+/CD44+ in human colon cancer and liver metastasis , 2013, Journal of cellular physiology.

[42]  Guo-tao Lu,et al.  A High Level of Integrin α6 Expression in Human Intrahepatic Cholangiocarcinoma Cells Is Associated with a Migratory and Invasive Phenotype , 2013, Digestive Diseases and Sciences.

[43]  F. Papaccio,et al.  Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[44]  T. Utsunomiya,et al.  High expression of cancer stem cell markers in cholangiolocellular carcinoma , 2012, Surgery Today.

[45]  Johan Lennartsson,et al.  Stem cell factor receptor/c-Kit: from basic science to clinical implications. , 2012, Physiological reviews.

[46]  M. Nagino,et al.  Recent advances in cancer stem cell research for cholangiocarcinoma , 2012, Journal of hepato-biliary-pancreatic sciences.

[47]  H. Saya,et al.  Tumor necrosis factor-α (TNF-α) stimulates the epithelial–mesenchymal transition regulator Snail in cholangiocarcinoma , 2012, Medical Oncology.

[48]  Haitao Zhu,et al.  Oct4 and Sox2 are overexpressed in human neuroblastoma and inhibited by chemotherapy. , 2012, Oncology reports.

[49]  T. Boonmars,et al.  Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma , 2012, Tumor Biology.

[50]  K. Dou,et al.  Notch is the key factor in the process of fetal liver stem/progenitor cells differentiation into hepatocytes , 2012, Development, growth & differentiation.

[51]  Quansheng Zhou,et al.  Deciphering the Key Features of Malignant Tumor Microenvironment for Anti-cancer Therapy , 2012, Cancer Microenvironment.

[52]  S. Glaser,et al.  Role of stem cell factor and granulocyte colony‐stimulating factor in remodeling during liver regeneration , 2012, Hepatology.

[53]  Scott M Lippman,et al.  Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy , 2012, Expert opinion on therapeutic targets.

[54]  R. Tohtong,et al.  Expression of CD24 in cholangiocarcinoma cells is associated with disease progression and reduced patient survival. , 2011, International journal of oncology.

[55]  R. Tohtong,et al.  Silencing of CD44 by siRNA suppressed invasion, migration and adhesion to matrix, but not secretion of MMPs, of cholangiocarcinoma cells , 2011, Clinical & Experimental Metastasis.

[56]  Hongxiang Liu,et al.  CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma , 2011, BMC Cancer.

[57]  A. Diehl,et al.  Hedgehog signaling in cholangiocytes , 2011, Current opinion in gastroenterology.

[58]  K. Leelawat,et al.  Strong expression of CD133 is associated with increased cholangiocarcinoma progression. , 2011, World journal of gastroenterology.

[59]  L. Vermeulen,et al.  Cancer stem cell niche: the place to be. , 2011, Cancer research.

[60]  A. Diehl,et al.  Hedgehog signaling in the liver. , 2011, Journal of hepatology.

[61]  A. Torrice,et al.  Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors. , 2010, World journal of gastrointestinal oncology.

[62]  A. Zhu,et al.  The role of signaling pathways in the development and treatment of hepatocellular carcinoma , 2010, Oncogene.

[63]  D. Alvaro,et al.  Descriptive epidemiology of cholangiocarcinoma in Italy. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[64]  Yasunori Sato,et al.  Epithelial-mesenchymal transition induced by transforming growth factor-{beta}1/Snail activation aggravates invasive growth of cholangiocarcinoma. , 2010, The American journal of pathology.

[65]  J. Mössner,et al.  Molecular targeted therapy of biliary tract cancer--results of the first clinical studies. , 2010, Current drug targets.

[66]  N. Cho,et al.  CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells , 2010, Oncogene.

[67]  T. Utsunomiya,et al.  CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma , 2010, Journal of Gastroenterology.

[68]  R. Tuan,et al.  Regulation of stemness and stem cell niche of mesenchymal stem cells: Implications in tumorigenesis and metastasis , 2010, Journal of cellular physiology.

[69]  Jie Ma,et al.  Tumor initiation in human malignant melanoma and potential cancer therapies. , 2010, Anti-cancer agents in medicinal chemistry.

[70]  F. Haller,et al.  Expression of stem cell factor receptor c-kit in human nontumoral and tumoral hepatic cells , 2009, European journal of gastroenterology & hepatology.

[71]  G. Ramadori,et al.  Expression of stem cell factor and its receptor c-Kit during the development of intrahepatic cholangiocarcinoma , 2009, Laboratory Investigation.

[72]  X. Wang,et al.  EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.

[73]  C. Cavaliere,et al.  Detection and Characterization of CD133+ Cancer Stem Cells in Human Solid Tumours , 2008, PloS one.

[74]  K. Kinoshita,et al.  Activation‐induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma , 2008, Hepatology.

[75]  K. Schmid,et al.  AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma. , 2007, World journal of gastroenterology.

[76]  Michael F Clarke,et al.  The biology of cancer stem cells. , 2007, Annual review of cell and developmental biology.

[77]  A. Iwama,et al.  Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. , 2007, Gastroenterology.

[78]  A. Elsharkawy,et al.  Nuclear factor‐κB and the hepatic inflammation‐fibrosis‐cancer axis , 2007 .

[79]  T. Khoury,et al.  CD24 Expression is an Independent Prognostic Marker in Cholangiocarcinoma , 2007, Journal of Gastrointestinal Surgery.

[80]  D. Scadden,et al.  The stem-cell niche as an entity of action , 2006, Nature.

[81]  Y. Jeng,et al.  CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma. , 2006, Cancer letters.

[82]  W. Weichert,et al.  Cytoplasmic CD24 Expression in Colorectal Cancer Independently Correlates with Shortened Patient Survival , 2005, Clinical Cancer Research.

[83]  M. Olnes,et al.  A Review and Update on Cholangiocarcinoma , 2004, Oncology.

[84]  H. El‐Serag,et al.  The epidemiology of cholangiocarcinoma. , 2004, Seminars in liver disease.

[85]  N. Theise,et al.  Canals of Hering: recent insights and current knowledge. , 2004, Seminars in liver disease.

[86]  King-Teh Lee,et al.  Expression of Transforming Growth Factor Betas and Their Signaling Receptors in Stone-containing Intrahepatic Bile Ducts and Cholangiocarcinoma , 2003, World Journal of Surgery.

[87]  G. Gores Cholangiocarcinoma: Current concepts and insights , 2003, Hepatology.

[88]  M. Ladanyi,et al.  Combined Hepatocellular–Cholangiocarcinoma: A Histopathologic, Immunohistochemical, and In Situ Hybridization Study , 2002, The American journal of surgical pathology.

[89]  T. Patel,et al.  Worldwide trends in mortality from biliary tract malignancies , 2002, BMC Cancer.

[90]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[91]  J. V. van Krieken,et al.  Expression of Ep‐CAM in normal, regenerating, metaplastic, and neoplastic liver , 1999, The Journal of pathology.

[92]  M. Kojiro,et al.  A Clinicopathological study on combined hepatocellular and cholangiocarcinoma , 1996, Journal of gastroenterology and hepatology.

[93]  S. Mukerjee,et al.  CHOLANGIOLOCELLULAR CARCINOMA OF THE LIVER. , 1964, Journal of the Indian Medical Association.

[94]  P. Steiner,et al.  Cholangiolocellular carcinoma of the liver , 1959, Cancer.

[95]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[96]  M. Manns,et al.  A critical role for notch signaling in the formation of cholangiocellular carcinomas. , 2013, Cancer cell.

[97]  C. Wongkham,et al.  Aberrant expression of CD44 in bile duct cancer correlates with poor prognosis. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[98]  Chong Gao,et al.  The role of stem cell factor SALL4 in leukemogenesis. , 2011, Critical reviews in oncogenesis.

[99]  M. Hamaguchi,et al.  Inflammation and tumor progression: a lesson from TNF-alpha-dependent FAK signaling in cholangiocarcinoma. , 2009, Methods in molecular biology.

[100]  徳本 憲昭 Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas , 2006 .

[101]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[102]  P. Steiner Carcinoma of the liver in the United States. , 1957, Acta - Unio Internationalis Contra Cancrum.